Logo

AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study to Treat COPD

Share this

AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study to Treat COPD

Shots:

  • The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] in 8-500+ patients with mod. to sev. COPD and a history of exacerbation(s) in the previous year- receiving at least two inhaled maintenance treatments at entry into the study
  • Results: 24% reduction in exacerbations; 46% reduction in the risk of all-cause mortality when compared with Bevespi Aerosphere- showed a 13% reduction in exacerbations compared with PT009. Additionally- demonstrated a reduction in the rate of mod. or sev. exacerbations at the half dose of budesonide
  • Breztri Aerosphere is an approved therapy in Japan and China for patients with COPD and is under regulatory review in the US and EU. As per the agreement to acquire Pearl Therapeutics- AstraZeneca will pay $150M as milestone upon US approval of the therapy for COPD

Click here to read full press release/ article 

Ref: AstraZeneca | Image: Pharmaceutical Technology

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions